Ahmed A Arif1, Colin Mitchell2. 1. University of North Carolina at Charlotte, Charlotte, NC, USA aarif@uncc.edu. 2. Walden University, Minneapolis, MN, USA.
Abstract
BACKGROUND: Chronic obstructive pulmonary disease (COPD), a progressive and nonreversible disease, is a leading cause of mortality and morbidity throughout the world. Because airway inflammation is a hallmark of COPD, it has been proposed that measuring exhaled nitric oxide, a marker of inflammation, in exhaled breath condensate could prove to be an inexpensive and efficient method to detect COPD in outpatient settings. METHODS: This study used secondary data on a sample of 10,214 individuals 30 years and older from the National Health and Nutrition Examination Survey 2007 to 2010. Binary and ordinal logistic regression analyses were used to test the association of exhaled nitric oxide (eNO) with COPD and COPD severity. RESULTS: The prevalence of COPD was 7.2%, based on self-reported physician diagnoses and 11.4% based on prebronchodilator spirometry analysis. This study found no statistically significant association between eNO, COPD, and COPD severity (P > .05). CONCLUSIONS: The findings of this study do not support use of eNO as a biomarker of inflammation in diagnosis and management of COPD.
BACKGROUND:Chronic obstructive pulmonary disease (COPD), a progressive and nonreversible disease, is a leading cause of mortality and morbidity throughout the world. Because airway inflammation is a hallmark of COPD, it has been proposed that measuring exhaled nitric oxide, a marker of inflammation, in exhaled breath condensate could prove to be an inexpensive and efficient method to detect COPD in outpatient settings. METHODS: This study used secondary data on a sample of 10,214 individuals 30 years and older from the National Health and Nutrition Examination Survey 2007 to 2010. Binary and ordinal logistic regression analyses were used to test the association of exhaled nitric oxide (eNO) with COPD and COPD severity. RESULTS: The prevalence of COPD was 7.2%, based on self-reported physician diagnoses and 11.4% based on prebronchodilator spirometry analysis. This study found no statistically significant association between eNO, COPD, and COPD severity (P > .05). CONCLUSIONS: The findings of this study do not support use of eNO as a biomarker of inflammation in diagnosis and management of COPD.
Authors: Anne Lindberg; A Bjerg; Anders Bjerg-Bäcklund; Eva Rönmark; Lars-Gunnar Larsson; Bo Lundbäck Journal: Respir Med Date: 2005-06-21 Impact factor: 3.415
Authors: Roberto de Marco; Giancarlo Pesce; Alessandro Marcon; Simone Accordini; Leonardo Antonicelli; Massimiliano Bugiani; Lucio Casali; Marcello Ferrari; Gabriele Nicolini; Maria Grazia Panico; Pietro Pirina; Maria Elisabetta Zanolin; Isa Cerveri; Giuseppe Verlato Journal: PLoS One Date: 2013-05-10 Impact factor: 3.240